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Abstract
p53 plays a pivotal role in controlling the differentiation of mesenchymal stem cells (MSCs) by regulating genes involved in
cell cycle and early steps of differentiation process. In the context of osteogenic differentiation of MSCs and bone
homeostasis, the osteoprotegerin/receptor activator of NF-κB ligand/receptor activator of NF-κB (OPG/RANKL/RANK)
axis is a critical signaling pathway. The absence or loss of function of p53 has been implicated in aberrant osteogenic
differentiation of MSCs that results in higher bone formation versus erosion, leading to an unbalanced bone remodeling.
Here, we show by microCT that mice with p53 deletion systemically or specifically in mesenchymal cells possess
significantly higher bone density than their respective littermate controls. There is a negative correlation between p53 and
OPG both in vivo by analysis of serum from p53+/+, p53+/−, and p53−/− mice and in vitro by p53 knockdown and ChIP
assay in MSCs. Notably, high expression of Opg or its combination with low level of p53 are prominent features in clinical
cancer lesion of osteosarcoma and prostate cancer respectively, which correlate with poor survival. Intra-bone marrow
injection of prostate cancer cells, together with androgen can suppress p53 expression and enhance local Opg expression,
leading to an enhancement of bone density. Our results support the notion that MSCs, as osteoblast progenitor cells and one
major component of bone microenvironment, represent a cellular source of OPG, whose amount is regulated by the
p53 status. It also highlights a key role for the p53-OPG axis in regulating the cancer associated bone remodeling.
Introduction
Bone remodeling is an exquisitely coordinated physiologi-
cal process that guarantees a balance between bone for-
mation and bone degradation to replace old or damaged
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bone. This process is orchestrated by cellular and molecular
mechanisms occurring in osteoblasts, cells generating bone,
and osteoclasts, cells degrading bone. To ensure a balanced
remodeling, it is necessary that osteoblasts and osteoclasts
generate and resorb the same amount of bone, phenomena
indicated as “coupling” [1, 2].
This process is driven by bone morphogenetic proteins
that after binding to their specific receptors activate runt-
related transcription factor 2 (RUNX2), a master gene in
regulating the complete differentiation of mesenchymal
stem cells (MSCs) toward osteoblasts. Another important
pathway regulating osteogenic differentiation of MSCs is
the WNT-Frizzled-β-catenin pathway [3]. The WNT path-
way can be inhibited by distinct molecules such as
Dickkopf-related protein 1 secreted by various cell types in
normal tissues and cytokines-activated malignant cells
which can impair osteoblasts functionality [4]. Osteoclasts
arise from hematopoietic stem cells that firstly differentiate
toward the monocyte/macrophage lineage through the
macrophage-colony stimulating factor (M-CSF). Next step
involves the activation of the receptor activator of nuclear
factor-κB ligand (RANKL). The binding of RANKL to
RANK will start different signal transduction pathways by
tumor necrosis factor (TNF) receptor-associated factor 6,
nuclear factor-κB (NF-κb), and c-Jun-N terminal kinase
(JNK/C Jun/fos).
Of note, a common and close niche in the bone marrow
has been proposed for both osteoblasts and osteoclasts
meaning that they can strictly influence and regulate each
other by direct cell contact or by other mechanisms [5, 6].
The OPG/RANKL/RANK axis has been found to be crucial
for bone remodeling [1, 7]. OPG is a member of the TNF
receptor family which acts as a soluble decoy receptor to
inhibit osteoclastogenesis [8]. It can suppress the activity
and survival of osteoclasts through sequestering RANKL
[9, 10] from binding to RANK on the surface of osteoclast
cells. In addition, OPG was recently found to be highly
expressed in advanced prostate cancer patients with bone
metastasis, confirming a role in tumor progression [11].
Deletion of OPG results in a severe osteoporosis and vas-
cular calcification due to enhanced bone resorption [12].
Oppositely, osteoporotic mice (op/op) reveal a loss of pro-
genitor cells for both osteoclasts and macrophages with
higher bone density [13].
In this context, the transcription factor p53, a well-known
regulator of DNA damage response and cell death [14–20]
plays a determinant role as a negative regulator of osteo-
genesis and osteoblast differentiation [21, 22]. Indeed,
while p53 is a powerful regulator of cell death, a crucial
mechanism for its role in cancer development [23–26], it
has a basic effect on metabolism [27, 28] and other biologic
processes [28, 29] including the regulation of MSCs
[30, 31]. It is evident that cancer cells can selectively silence
p53 activities in cancer stromal cells, thereby molding the
cancer stroma to facilitate cancer progression [32, 33].
Indeed, inactivation of p53 and retinoblastoma gene in bone
marrow derived MSCs can promote the development of
osteosarcoma-like cancer when transplanted in immunode-
ficient mice [34]. Despite recent advances, the functions and
potential molecular regulations of p53 in MSC biology
during cancer progression are not fully understood.
Here, we hypothesize that there are unexplored main
factors potentially contributing to the osteosclerotic-like
phenotype observed in p53−/− mice including: (i) p53
regulation of the molecular secretion profile of MSCs, (ii)
correlation of p53 and the OPG/RANKL axis in MSCs, and
(iii) p53 regulation of monocytes differentiation towards
osteoclasts. By the selective deletion of p53 in mesenchy-
mal cells, we show that p53 negatively regulates the
expression of OPG in MSCs both in vitro and in vivo. More
importantly, high level of OPG is correlated with a poor
prognostic in both prostate cancer and osteosarcoma. In a
prostate cancer metastasis model, impaired p53 expression
can promote Opg expression, and enhance bone
density. Overall, we speculate that p53 constrains sig-
nificantly the differentiation potential of osteoclast pro-
genitor cells toward osteoclasts, and constructs the
metastatic niche of prostate cancer through the regulation of
OPG expression.
Results
Loss of p53 impairs bone homeostasis and OPG/
RANKL ratio
p53 inactivation induced by mutations occurs in more than
half of all cancer patients including prostate cancer and
osteosarcoma [32]. The progression of these cancers is
always accompanied by aberrant bone remodeling [35].
Considering the tight interplay between p53 and the process
of bone homeostasis [36], we decided to investigate the link
between p53 and bone biology in vivo. To do so, we ana-
lyzed both femurs and tibias harvested from mice with
different p53 status by micro computed tomography
(microCT) (Fig. 1a). As previously demonstrated [21],
quantitative analysis revealed a significant increase in bone
density in p53−/− mice as compared to p53+/+ and p53+/−
control littermates (Fig. 1c). Notably, a significant increase
in trabecular thickness was found in p53−/− mice compared
to p53+/+ controls (Fig. 1d), whereas no significant differ-
ence was observed in cortical bone (Fig. 1e). Histologically,
haematoxylin and eosin staining performed on decalcified
bone sections of p53+/+, p53 +/−, and p53−/− mice verified
the results of the microCT (Fig. 1b). Because the OPG/
RANKL axis plays a key role in bone remodeling and their
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ratio is a measure of osteoclast activation [37], we aimed to
investigate their interplay with the p53 status. Serum from
p53+/+, p53+/−, and p53−/− mice was collected and protein
levels of OPG and RANKL were assessed by the enzyme
linked immunosorbent assay (ELISA). We found a
significantly higher level of OPG in the serum of p53−/−
mice compared to p53+/+ ones (Fig. 1f). On the other side,
no significant difference was observed for the concentration
of RANKL (Fig. 1g). Furthermore, a significant increase in
the OPG/RANKL ratio was found in the serum of p53−/−
Fig. 1 Loss of p53 impairs bone homeostasis and the normal OPG/
RANKL ratio. Representative images of microCT (a) and H&E
staining (b) of bone from p53+/+, p53+/−, and p53−/− mice. Scale bar
represents 100 µm, n= 5. Quantification of bone volume relative to
total volume (c), trabecular bone thickness (d), and cortical bone
thickness (e) from representative microCT scans in a, n= 5. Serum
OPG (f) and RANKL (g) were measured in p53−/− (n= 6), p53+/−
(n= 6), p53+/+ (n= 6) mice. h RANKL/OPG ratio was calculated
according the serum values of OPG and RANKL obtained in f and g. i,
j Overall survival of prostate cancer patients was analyzed by Syner-
gy2G. GSE16560 was selected. 30 samples from batch 6 (i) and
64 samples from batch 4 (j) were shown as plots. OPGhighTP53low or
OPGlowTP53high were shown as blue, and the others were shown as
red. Data are presented as mean ± SD. *p < 0.05, **p < 0.01, n.s. not
significant. All replicates are biological replicates.
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mice, suggesting an impaired osteoclasts activity in the
absence of p53 (Fig. 1h).
Assuming that the OPG/RANKL ratio is a measure of
osteoclasts activation and that it has been negatively asso-
ciated with the progression of bone degradation in an
independent mechanism from inflammation [38], we injec-
ted RANKL subcutaneously over the femur of wild-type
and p53−/− mice according to an established protocol [39]
in order to evaluate whether: (i) it could affect OPG/
RANKL ratio, or (ii) alteration of the OPG/RANKL ratio
could affect bone formation. Interestingly, we found a sig-
nificant decrease of trabecular thickness and a slight
decrease of bone/total volume in p53−/− mice injected with
RANKL compared to the control mice (Fig. S1a, b).
To reveal the role of p53 and OPG in cancer associated
bone remodeling, we use Synergy2G (www.bioprofiling.de/
synergy2g) to explore their correlation in prostate cancer
patients [40, 41]. In GSE16560, OPGhighTP53low patients
showed poor prognosis while OPGlowTP53high patients
showed better overall survival, indicating a potential rela-
tionship between p53 and OPG in determination of the pro-
gression of prostate cancer (Fig. 1i, j). Given that the
metastatic lesion in prostate cancers are prone to be osteo-
blastic instead of osteolytic, the correlation between TP53/
OPG expression and overall survival could point to the pos-
sibility that low expression of TP53 and high expression of
OPG in prostate cancer would induce the enhancement of
bone density and set up a metastatic niche. Also, OPG can
serve as a potential prognostic biomarker in Ewing sarcoma.
Kaplan–Meier analysis showed that low level of OPG is
associated with higher event-free survival (Fig. S1c, d) and
overall survival (Fig. S1e) in patients with mixed Ewing
sarcoma and tumor Ewing sarcoma, respectively. In addition,
OPG expression has an opposite prognostic value in patients
with mixed Ewing sarcoma, however, the analysis fails to
reach statistical significance (Fig. S1f). Collectively, all these
data suggest that p53 could affect bone remodeling indirectly
and contributing to higher bone intake, and thus abnormal p53
expression in cancer patients may regulate pathological bone
remodeling and tumor progression through OPG.
p53 deficiency alters the osteogenic differentiation
of MSCs
MSCs represent a population of multipotent progenitor cells
that can generate various mesenchymal lineages under spe-
cific in vitro culture condition [42, 43]. Importantly, MSCs
resident in the bone marrow can assist the regeneration of
mesenchymal tissues such as adipose, cartilage, and bone
[44]. Therefore, according to the significantly higher bone
density and trabecular bone thickness detected in p53 defi-
cient mice, we thought to further investigate the role of p53
in bone homeostasis during osteogenic differentiation of
mouse derived MSCs. To do so, we generated p53f/
fDermo1-cre mice that induce a specific deletion of p53 in
MSCs, a cell source for generation of osteoblasts. Similar to
that in p53 deficiency mice, p53f/fDermo1-cre mice exhib-
ited much higher bone density compared to that of littermate
controls (Fig. 2a, b). To investigate whether p53 directly
regulated MSC differentiation, we isolated MSCs from bone
marrow of p53+/+ and p53−/− mice as previously described
[45]. p53 expression was shown to be undetectable in
p53−/− MSCs by real-time qPCR and western blotting
analysis matching with the mouse genotype (Fig. S2a, b).
Both p53+/+ and p53−/− MSCs showed a common
phenotype of MSCs: CD44+, Sca-1+, CD140a+, CD13+,
MHC II−, CD11c−, CD11b−, CD86−, and CD45−
(Fig. S2c), indicating that p53 deficiency did not affect MSC
phenotypic markers. To investigate whether p53 regulates
osteogenesis of MSCs, we cultured p53+/+ and p53−/−
MSCs in the appropriate osteogenic differentiation medium
[46]. Alizarin red staining performed at different time points
of the osteogenic differentiation of MSCs revealed that p53
deficient cells exhibited an accelerated differentiation com-
pared to wild-type MSCs (Fig. 2c). Real-time qPCR for
osteogenic transcription factors involved in the early phases
of osteogenic differentiation such as Osterix (Osx) and
Runx2 [47] revealed their upregulation existed in p53−/−
MSCs compared to p53+/+ even without the osteogenic
differentiation (Fig. 2d).
OPG production is increased in p53 deficient MSCs
OPG is a member of the tumor necrosis factor receptor
family that functions as soluble decoy receptor and inhibitor
for RANKL via abrogating its interaction with RANK
expressed on the surface of progenitor and mature osteoclasts
[48]. However, it has not been reported whether bone mar-
row derived MSCs as osteoblasts precursors could represent
a source for the production of OPG. For this reason, we
analyzed OPG expression by real-time qPCR and ELISA
in p53+/+ and p53−/− MSCs. Compared to p53+/+ MSCs,
p53−/− MSCs exhibited higher expression and production of
OPG at both mRNA and protein levels (Fig. 3a, b). These
results indicate that p53 deficiency affected OPG production
in MSCs, however, the changes detected in these MSCs
could occur sequentially following a developmental effect of
p53 loss on MSCs. To bypass this issue and to further cor-
roborate the direct role of p53 in MSCs, we used short
hairpin RNA to knock down p53 in MSCs. A successful
knockdown of p53 in MSCs was demonstrated at mRNA
and protein levels (Fig. 3c, d). Interestingly, we found that
Opg mRNA and protein significantly increased in p53
knockdown MSCs (Fig. 3e, f), confirming that MSCs can act
as a source for the production of OPG and p53 has a negative
effect on OPG expression in MSCs.
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To further investigate the negative effect of p53 on Opg
expression in MSCs, p53+/+ MSCs were treated with the
inhibitor Nutlin-3 to block the interaction between p53 and
murine double minute 2. The upregulation of p53 mediated
by Nutlin-3 treatment (Fig. 3g) repressed the expression of
Opg in wild-type MSCs (Fig. 3h), confirming a negative
regulation of OPG by p53 in MSCs. In addition, when p53
was upregulated following treatment with cisplatin to
induce DNA damage (Fig. S3a–c), we observed a decrease
in the Opg expression in p53+/+ MSCs (Fig. S3d). Next, we
assessed whether p53 could also regulate the expression of
OPG in human MSCs. To this end, we successfully
knocked down p53 with shRNA in human umbilical cord
derived MSCs (hUC-MSCs) as shown in Fig. S3e, f.
Similar to what we observed in mouse derived MSCs, we
found that the knockdown of p53 in hUC-MSCs promoted a
significant increase of OPG expression (Fig. S3g). To test
whether p53 represses the transcription of Opg through
binding its promoter, we performed a chromatin immuno-
precipitation assay (ChIP). As shown in Fig. 3i, p53 sig-
nificantly associates with the Opg promoter in wild-type
MSCs as compared to p53 deficient MSCs, suggesting that
p53 represses the transcription of Opg by binding to the
Opg promoter.
Osteoclasts derived from p53−/− monocytes exhibit
impaired functionality
Bone remodeling is a process balanced through bone for-
mation and bone resorption, with the latter mediated by
mature and functional osteoclasts [2]. To extend the phe-
nomena to the more general regulation of bone physiology,
we assessed whether the absence of p53 could also affect
osteoclast differentiation [49]. To this purpose, we isolated
Fig. 2 p53 deficiency alters the
osteogenic differentiation of
MSCs. a Representative
microCT images from p53f/f
(n= 4) or p53f/fDermo1-cre
(n= 3) mice. b Quantification of
bone volume relative to total
volume (left) and bone surface
density (right) from
representative microCT scans in
a. c p53+/+ and p53−/− MSCs
were cultured in osteogenic
differentiation medium for
indicated days and stained with
Alizarin Red S. d p53+/+ and
p53−/− MSCs were analyzed for
Osterix, Runx2 mRNA to verify
their basal level expression. Data
are presented as mean ± SD (b)
or mean ± SEM (d). *p < 0.05,
**p < 0.01, ***p < 0.001. All
experiments were repeated at
least twice (biological replicas)
with identical or comparable
results.
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monocytes from bone marrow of p53+/+ and p53−/− mice
as previously described [50]. We found an increase in the
percentage of Ly6C+ CD11b+ cells in p53−/− mice com-
pared to control mice (Fig. S4a, b). Then, we differentiated
the isolated monocytes towards osteoclasts using condi-
tional medium culture as previously reported [6, 50].
The differentiation of osteoclasts was investigated by tar-
trate resistant acid phosphatase (TRAP) staining and by
real-time qPCR for specific genes expressed in mature
osteoclasts. TRAP staining revealed higher percentage
osteoclasts formation in monocytes derived from p53+/+
mice compared to that from p53−/− mice (Fig. 4a–c). Along
the osteoclast differentiation process, pre-osteoclasts fuse
each other into mature multinucleated cells that are recog-
nized to be active through the expression of key osteoclasts
markers, such as: Trap and αVβ3 integrin chains
Fig. 3 OPG production is increased in p53 deficient MSCs.
a Quantification of Opg mRNA expression in p53+/+ and p53−/−
MSCs by real-time qPCR. b Quantification of OPG protein levels in
the culture supernatant from p53+/+ or p53−/− MSCs. c, d p53+/+
MSCs were transfected with p53 short hairpin RNA lentiviral particles
(shp53) or control shRNA (shCtrl). After infection, cells were selected
through puromycin selection (3 µg/ml) for 3 days. MSCs were ana-
lyzed for both p53 mRNA (c) and protein (d), to verify the efficiency
of knockdown. e Quantification of Opg mRNA expression in shp53
and shCtrl MSCs. f Quantification of OPG protein levels in culture
supernatants from shp53 and shCtrl MSCs. g, h Mouse bone marrow
derived p53+/+ MSCs were treated with nutlin-3 (5 µM) or DMSO
(vehicle control) for 24 h and then lysed and analyzed for p53 (g) and
Opg (h) mRNA expression by qPCR. i Chromatin immunoprecipita-
tion (ChIP) analysis was performed using anti-p53 antibodies or IgG
for immunoprecipitation and subsequently analyzed with Opg pro-
moter specific PCR. Data are presented as mean ± SEM. **p < 0.01,
***p < 0.001. n.s. not significant. These results are representatives of
three independent experiments with similar results.
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(β3 integrin, Itgb3) [51]. We observed a significant reduc-
tion of mRNA expression of Trap enzyme as well as Itgb3
in the absence of p53 (Fig. 4d, e). These results indicated
that monocytes derived from p53−/− mice was impaired in
achieving a complete osteoclast differentiation. Moreover,
in order to investigate whether in a p53 null landscape the
higher expression of Opg from MSCs could affect osteo-
clast maturation, we also implemented OPG protein in
the conditional medium along with RANKL and M-CSF in
the cultures of monocytes as previously mentioned. In these
conditions, wild-type monocytes treated with OPG were
less TRAP+ (Fig. 4a–c) and had a significant reduction in
Trap, Itgb3 mRNA expression (Fig. 4d, e). Taking together,
these data indicate that OPG can function as inhibitor of
RANKL and induce a decreased differentiation capability in
monocytes derived from wild-type mice versus osteoclasts
but has less impact in the p53 null conditions.
Regulation of the p53/OPG axis by androgen
promotes bone remodeling in prostate cancer mice
Given that the negative correlation between p53 and OPG is
related to prognostic of prostate cancer, we further inves-
tigated the role of the p53/OPG axis in preparing the bone
metastatic niche during prostate cancer progression. We
questioned if the prominent hormone acting on prostate
cancer would affect p53 status and the bone homeostasis.
As some prostate cancer cells acquired the ability to make
testosterone [52], to this end, we firstly used ELISA to assay
the testosterone production by different prostate cancer cell
lines, including DU145, LNCaP, and PC3 (Fig. 5a). Among
them, a comparable level was demonstrated. To reveal the
effect of androgen on p53 status, dihydrotestosterone
(DHT) was added to hUC-MSCs treated with hydrogen
peroxide (Fig. 5b). As expected, p53 was induced with the
addition of hydrogen peroxide (H2O2) and significantly
suppressed in the presence of DHT. Thus, enriched andro-
gen is one of the reasons to induce the loss of activity of p53
in MSCs. We further constructed a bone metastatic model
of prostate cancer by intra-bone injection of 22Rv1 cells, a
prostate cancer cell line with less androgen production.
During this process, 22Rv1 cells were intra-bone injected to
the right femur, with s.c administration of corn oil or tes-
tosterone three times per week for 8 weeks (Fig. 5c). Right
femur and left femur were then analyzed by microCT. As
demonstrated, the percentage of bone volume, bone surface
density, and trabecular number in the right femur (with
prostate cancer cell injection) were much higher in
testosterone-injected mice than those of corn oil injected
control mice (Fig. 5d–g). By employment of immunos-
taining, we found that in contrast to control group, the right
femur in testosterone-injected mice showed lower level of
p53 and higher level of OPG (Fig. 5h). Taken together,
these results demonstrate that prostate cancer cells modulate
the p53/OPG axis in MSCs and their osteogenesis via
androgen, and build up the bone metastatic niche.
Fig. 4 Osteoclasts derived from p53−/− monocytes exhibit impaired
functionality. a Representative images of osteoclast stained by
T2RAP (red) after treatment for 7 days in specific medium plus 25 ng/
ml M-CSF, 50 ng/ml RANKL, with or without OPG (50 ng/ml). Scale
bar represents 50 µm. b, c Quantification of nuclei per osteoclast and
TRAP + osteoclasts per field as shown in a. Quantification for Trap (d)
and Itgb3 (e) mRNA expression of experiment shown in a. Data are
shown as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. not
significant. The experiments were repeated at least twice (biological
replicates) with similar results.
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Discussion
Our findings revealed a strong association among p53
deficiency, high levels of OPG, and more bone formation
(Fig. 6). Following the original hypothesis that osteoblasts
and stromal cells could regulate osteoclasts formation,
activity, and bone resorption [53, 54], OPG was reported
by several groups to protect the bone from excessive bone
resorption and to inhibit osteoclasts activity by binding
RANKL and hence avoiding its binding to RANK
receptor [55]. In keeping with the crucial role of the OPG/
RANKL axis in bone biology, here we demonstrate that
bone marrow derived MSCs are a source of OPG pro-
duction. We found that p53 deficiency promoted a sig-
nificant increment in the production of OPG at serum level
and in bone marrow derived MSCs, indicating that the
Fig. 5 Regulation on the p53/OPG axis by androgen promotes
bone remodeling in prostate cancer. a Testosterone concentrations
in the culture supernatant from prostate cancer cell lines (DU145,
LNCaP, and PC3) were analyzed by ELISA. b MSCs were treated
with hydrogen peroxide (2 mM) alone or combined with dihy-
drotestosterone (DHT, 100 nM) for 6 h. p53 mRNA level was then
analyzed by qPCR. c–f Human prostate cancer cell line 22Rv1 cells
were intra-bone injected to the right femur of nude mice, with s.c
administration of corn oil or testosterone (200 μg/mouse) three times
per week for 8 weeks. c Schematic diagram of the tumorigenesis
model. Quantification of Bone/total volume (d), bone surface density
(e), and trabecular number (f) of the left and right femur by microCT
(n ≥ 4). g Representative 3D reconstructing image of MicroCT of right
femur with the administration of either testosterone or corn oil.
h Immunohistostaining showed p53 and OPG levels in right femur.
Top line was representative image of corn oil-treated control group and
bottom line showed the testosterone-treated group. p53, OPG, and
Hoechst were shown as green, red, and blue, respectively. Scale bar
represents 200 μm. Data are shown as mean ± SD. *p < 0.05, n.s. not
significant.
T. Velletri et al.
production of OPG from MSCs can be modulated by
p53 status.
Of note, we observed a significant increase in bone density
and trabecular bone thickness, but not in cortical bone in p53
null mice. This can be explained by the different anatomic
location and composition of the trabeculae compared to
the cortical bone. Indeed in the trabecular bone, the trabeculae
are interspersed in the bone marrow that represent the bone
remodeling compartment containing bone marrow progenitor
cells and is invaded by blood vessels which replace hema-
topoietic stem cells precursors for osteoclasts [2]. On the other
hand, in the cortical bone, the blood and blood elements are
provided by the Haversian canals. The direct evidence that
loss of p53 contributes to the development of an aberrant
bone phenotype ask for new questions on the molecular
mechanism by which p53 coordinates osteoblasts and osteo-
clasts differentiation from their respective precursor cells. It
has been reported that p53 acted as a negative regulator
of osteoblastogenesis through repressing the expression of
Osterix, a transcription factor involved in the early phase of
osteogenic differentiation of osteoblast precursor cells [21].
Our findings reinforce the role of p53 in the regulation of
osteoblast differentiation by adding a layer of complexity.
First, we showed that p53 negatively regulated the expression
of Opg in MSCs by binding to its promoter. Previous studies
have demonstrated that p53 can suppress the expression of
certain genes directly or indirectly. In the context of p53
levels, cofactors or specific response element sequences used,
p53 was found to repress the expression of IL-6, VEGF-A,
and Osterix at the transcriptional level [21, 56–58]. The
indirect repressing activity of p53 on targeted genes could be
mediated by other DNA-binding proteins and co-repressors
such as the CAAT-binding factor [59]. Also, its indirect
regulation can be exerted by interference with the assembly of
the transcription-initiation complex, or recruitment of histone
deacetylase which functions as repressors of transcription
[60]. Therefore, further investigation focusing on elucidating
the molecular mechanism of p53 binding on Opg promoter
will provide critical information on the detailed regulation of
Opg expression by p53. Second, we revealed that p53 nega-
tively regulated osteoclast differentiation. In fact, monocytes
derived from p53−/− mice show an impaired differentiation
towards the osteoclast lineage. Moreover, secreted OPG did
not have effect on the growth rate of MSCs itself (data not
shown). Nevertheless, we show that the differentiation
potential of p53−/− monocytes into osteoclasts is also sig-
nificantly impaired when we supplement OPG to the condi-
tional medium for osteoclasts differentiation.
Opg deficient mice exhibit severe osteoporosis as a result
from increased osteoclast activity in bone resorption, along
with higher concentration of RANKL in the serum compared
to wild-type mice [61]. Interestingly, we found that RANKL
injection in femur of wild-type and p53−/− mice reduced bone
density and trabecular thickness. We performed our analysis
on mice <15-week-old to avoid the presence of tumor that
frequently occurs in p53 null condition and with higher fre-
quency in p53+/− mice [62]. We do not exclude the possibility
that along with age, MSCs as part of the tumor micro-
environment could secrete a new panel of molecules that can
further affect bone homeostasis and promote tumor develop-
ment or be recruited to the site of tumor formation, especially
considering the influence of oxidative stress, inflammation,
and tumor formation. Indeed, we provide evidence that bone
marrow derived MSCs are an important source of OPG, and
p53 negatively regulates its expression in prostate cancer bone
metastatic niche. We suggest a link between p53 functionality
in MSCs through the OPG/RANKL pathway, and we under-
line the importance of MSCs in regulating bone formation
Fig. 6 Schematic representation of the proposed molecular
mechanism by which p53 regulates bone remodeling. Enriched
testosterone produced by prostate cancer cells can suppress p53
expression in MSCs. These MSCs with p53 deficiency exhibit more
potential to generate osteoblasts and produce OPG. The enhanced
OPG production can block the RANKL-RANK signaling in
osteoclasts and results in an impairment of bone resorption. Such
concerted action modulated by p53 regulates the bone remodeling and
constructs the bone metastatic niche of prostate cancer. OPG osteo-
protegerin, RANKL receptor activator of nuclear factor κΒ ligand,
RANK receptor activator of nuclear factor-κB.
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through their functionality and immunomodulatory properties
modulated by p53. This, in the context of bone micro-
environment will provide new insights related to bone remo-
deling and physiology but also to determine mechanisms in
charge of disruption of bone homeostasis and dissociated
coupling in age and in bone tumor development.
Materials and methods
Reagents
The following antibodies were used in flow cytometry:
phycoerythrin (PE)-conjugated anti-mouse CD44 (Biole-
gend, 103007), Sca-I (eBioscience, 12-5981-83), CD140a
(Biolegend, 135906), CD13 (BD Pharmingen, 558745),
MHC II (eBioscience, 12-5320-80), CD11b (eBioscience,
12-0112-83), CD11c (eBioscience, 12-0114-82), CD86
(eBioscience, 12-0862-82), and CD45 (eBioscience, 12-
0451-82). Antibodies used for western blotting analysis
were: anti-p53 (FL-393; sc-6243, Santa Cruz Biotechnol-
ogy); GAPDH (14C10, 2118, Cell Signaling Technology).
Antibody used for Chip was: p53 (FL-393; sc-6243, Santa
Cruz Biotechnology), IgG (normal mouse IgG, sc2025,
Santa Cruz Biotechnology). The reagents for cell treatment
were: Nutlin-3 (Nutlin-3, Selleck Chemicals, Houston, TX,
USA), Cisplatin (Sigma-Aldrich), RANKL (recombinant
mouse RANKL, 50 ng/ml, R&D), M-CSF (recombinant
mouse M-CSF, 25 ng/ml, R&D), and OPG (recombinant
OPG, 50 ng/ml, Sigma-Aldrich). RANKL for mouse injec-
tion (recombinant mouse RANKL, 2 mg/kg/day) was from
R&D Systems.
Mice
C57BL/6 and nude mice were purchased from the Shanghai
Laboratory Animal Center of Chinese Academy of Sci-
ences, Shanghai, China. p53−/− mice were from Animal
Model Research Center of Nanjing University, Nanjing,
China. Dermo1-Cre mice were purchased from The Jackson
Laboratory (stock No. 008712). p53f/f mice were kindly
gifted by Dr. Jun Qin, Shanghai Institute of Nutrition and
Health. Mice were maintained under specific pathogen-free
conditions in the animal facility of Institute of Health Sci-
ences. All procedures were approved by the Institutional
Animal Care and Use Committee of the Shanghai Institute
of Nutrition and Health, Shanghai Institute for Biological
Sciences of Chinese Academy of Sciences.
Cells
MSCs were derived from bone marrow of the tibia and
femur of 6–8-week-old mice. The cells were cultured in
DMEM medium supplemented with 10% fetal bovine
serum (FBS), 2 mM glutamine, 100 U/ml penicillin, and
100 mg/ml streptomycin (all from Invitrogen, Carlsbad,
CA). Non-adherent cells were discarded after 24 h, and
adherent cells were maintained with medium replenished
every 3 days. At confluence, cells were harvested and see-
ded into 96-well plates by limited dilution. Individual
clones were picked and expanded. MSCs were character-
ized by their expression of cell surface markers and their
capability to differentiate into adipocytes and osteoblasts.
Cells were used before the 15th passage. Human UC–MSCs
were generated as previously described [63], and approved
by the institutional biomedical research ethics committee of
the Shanghai Institutes for Biological Sciences (Chinese
Academy of Sciences). Primary monocytes were isolated
from bone marrow flushed from the tibia of 7–8-week-old
wild-type and p53−/− C57BL/6 mice and filtered through a
70 µm cell-strainer. Cells were washed twice in fresh new
medium and plated overnight in αMEM plus 10% FBS.
Prostate cancer cell lines DU145, LNCaP, PC3, and 22Rv1
were provided by Dr. Jun Qin, Shanghai Institute of
Nutrition and Health.
Differentiation of MSCs
For osteogenic differentiation, MSCs were cultured in osteo-
genic differentiation medium: DMEM supplemented with
10% FBS, 10 nM dexamethasone, 10mM β-glyceropho-
sphate, and 100mM ascorbic acid. MSCs were seeded in 24-
well plate and maintained with osteogenic medium replen-
ished every 3 days. These cultures were stained at appropriate
time points with Alizarin Red S to identify calcium deposition,
an indication of osteoblasts activity. All reagents were pur-
chased from Sigma-Aldrich (St. Louis, MO).
Osteoclast differentiation assay
Bone marrow derived monocytes were isolated and then
differentiated to osteoclasts as previously reported [6]. Briefly,
1 × 106 non-adherent cells derived from overnight culture of
primary monocytes were plated in 24-well plate and supple-
mented with 50 ng/ml RANKL and 25 ng/ml M-CSF the next
day for 5 days with medium and cytokines replenishment
every 2 days. An additional group for osteoclast differentia-
tion was differentiated in the presence of 50 ng/ml OPG. Cells
were fixed, TRAP was stained on day 6 using a leukocyte
acid phosphatase kit (Sigma-Aldrich) and TRAP+ multi-
nucleated cells were considered as mature osteoclasts.
Histological and microCT analysis
Hind limb bones were excised from 15-week-old mice
without detectable tumor, fixed with 10% neutral-buffered
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formalin. One limb from each mouse was collected for
microCT analysis. The other hind limb was washed and
decalcified in a solution of 10% EDTA for 2 weeks and then
embedded in paraffin or Tissue-Tek® O.C.T.™ Compound
(Sakura). Paraffin sections were performed and stained with
hematoxylin and eosin (H&E). For the Immunofluorescence
staining, frozen sections were used and stained with anti-
p53 and anti-OPG antibody following a standard protocol.
Histological analysis was performed on sections of bones
stained with H&E using the Zeiss Axiovert 200 microscope,
and the AxioVision software version 4.6.3 SP1. MicroCT
images were reconstructed and analyzed by Shanghai
Showbio Biotech, Inc.
Chromatin immunoprecipitation
A Total of 2 × 106 cells were used for immunoprecipitation.
The MagnaChip system (Millipore) was used according to
the manufacturer’s instructions. Chromatin fragmentation
was carried out by sonication of cell extract by using a
Bioruptor sonicator with higher power for 30-s “on”/30-s
“off” cycles for 20 min. Immunoprecipitation was per-
formed using 8 µg anti-p53 antibody (Santa Cruz Bio-
technology). Rabbit IgG were used as a negative control.
DNA was purified and used as template for PCR reactions.
We used primer flanking the Opg promoter region in mouse
and in human. Primers for ChIP analysis were designed as
described in a previous study [64].
Lentiviral infection
Mouse and human p53 short hairpin RNA lentiviral parti-
cles were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). The lentiviral particles were added to the
culture medium of MSCs and incubated for 24 h before
puromycin screening. Cells were then selected through
puromycin (3 µg/ml) for 3 days.
Western blotting analysis
Cells were harvested by scraping from the culture dish and
washed twice with ice-cold phosphate buffered saline
(PBS). Total protein was extracted from the cell pellet with
RIPA lysis buffer (Upstate, Charlottesville, VA). Samples
were incubated on ice for 30 min and then centrifuged at
12,000 g for 20 min at 4 °C. Supernatants were collected
and mixed with sodium dodecyl sulfate sample buffer,
heated at 95 °C for 10 min and separated by polyacrylamide
gel electrophoresis and electrical blotted to poly-
vinylidenedifluoride membranes (Whatman, Inc., Clifton,
NJ). Membrane was incubated for 1 h at room temperature
in a blocking solution composed of 5% skimmed milk
powder dissolved in TBST (0.05% Tween-20, 10 mM Tris,
pH 8.0, and 140 mM NaCl). After washing the membrane
three times with TBST, proteins were revealed by mouse
and rabbit antibodies against p53, or GAPDH by overnight
incubation at 4 °C. After three washes with TBST, mem-
branes were incubated with anti-mouse or anti-rabbit sec-
ondary antibodies (Cell Signaling Technology, Inc.). The
blots were then subjected to chemiluminescent detection
according to the manufacturer’s instructions.
RNA extraction and qRT-PCR
Total RNA was extracted with TRIzol reagent (Invitrogen,
Carlsbad, CA) and reverse transcribed into cDNA using the
Taqman reverse transcription kit (ABI, Carlsbad, CA). The
levels of mRNA of interest genes were measured by real-
time qPCR (7900 HT by Applied BioSystems, Foster City,
CA, USA) using SYBR Green Master Mix (TaKara Bio-
tech). Total amount of mRNA was normalized to endo-
genous Actb mRNA. Sequences of PCR primer pairs are
listed in Table 1, in Supplementary Information.
Flow cytometry analysis
Cells were harvested and washed twice with PBS. The
cell pellets were resuspended in staining buffer (PBS, 3%-
FBS) at a density of 1 × 107 cells per milliliter. The cell
suspension (100 µl) was incubated for 30 min with
conjugated antibodies. Cell were washed twice with the
staining buffer, and analyzed by flow cytometry through a
FACS Calibur flow cytometer (Becton Dickinson, San
Jose, CA). Data were analyzed through FCS Express soft-
ware. At least 20,000 events were collected for each
analytical point.
ELISA immunoassay
Quantitative levels of murine OPG in the serum of p53+/+,
p53+/−, and p53−/− C57BL/6 mice and in the conditioned
medium of MSCs were determinate in triplicate by ELISA
according to the manufacturer’s protocol (Mouse OPG
Quantikine ELISA kit immunoassay, R&D). Quantitative
levels of murine RANKL in serum of p53+/+, p53+/−, and
p53−/− C57BL/6 were determined in triplicate by ELISA
according to the manufacturer’s protocol (Mouse RANKL
Quantikine ELISA kit immunoassay, R&D). Quantitative
levels of human OPG in conditioned medium of hUC were
determinate in triplicate by ELISA according to the manu-
facturer’s protocol (Human Osteoprotegerin TFRSF11b
ELISA kit, Sigma-Aldrich). Quantitative levels of testos-
terone were determined following the protocol of the Tes-
tosterone Parameter Assay Kit (R&D system).
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RANKL injection
Mouse recombinant RANKL (2 mg/kg/day) or vehicle was
injected subcutaneously over the femur, twice per day, for
5 days alternated by 2 days of rest. Mice were sacrificed on
the 6th day, and the hind limbs were excised and processed
for MicroCT analysis as already described.
Prostate cancer model
Human prostate cancer cell line 22Rv1 cells were intra-bone
injected to the right femur, with s.c administration of corn
oil or testosterone (200 μg/mouse) three times per week for
8 weeks.
Bioinformatic analysis
Bioinformatic analysis was carried out by using the fol-
lowing website: R2: Genomics Analysis and Visualization
Platform, https://r2.amc.nl. Adjustable settings: cutoff
modus: scan; Sample Filter: NO.
Overall survival of prostate cancer patients was analyzed
by Synergy2G at the website www.bioprofiling.de/
synergy2g. GSE16560 was selected. A total of 30 sam-
ples from batch 6 and 64 samples from batch 4 were used.
Statistical analysis
The GraphPad Prism 5.0 software (GraphPad software, Inc.,
San Diego, CA) was used for the statistical analysis. Sta-
tistical significance was assessed by unpaired two-tailed
Student’s test and stated as follow: n.s., not significant; *p
< 0.05; **p < 0.01; ***p < 0.001.
Sample size was estimated empirically, according to the
exploratory experiments and published literatures with similar
methodology. Since no suggestive analysis was involved in
this study, randomization, and blinding were not applied.
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